July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
One-year Outcomes of Fixed Treatment of Intravitreal Aflibercept for Exudative Age-related Macular Degeneration and the Factor of Visual Prognosis
Author Affiliations & Notes
  • Rie Osaka
    Kagawa University Faculty of Medicine, Kita-gun, Japan
  • Chieko Shiragami
    Kagawa University Faculty of Medicine, Kita-gun, Japan
  • Aoi Ono
    Kagawa University Faculty of Medicine, Kita-gun, Japan
  • Saki Manabe
    Kagawa University Faculty of Medicine, Kita-gun, Japan
  • Yukari Takasago
    Kagawa University Faculty of Medicine, Kita-gun, Japan
  • Mamoru Kobayashi
    Kagawa University Faculty of Medicine, Kita-gun, Japan
  • Ayana Yamashita
    Kagawa University Faculty of Medicine, Kita-gun, Japan
  • Kazuyuki Hirooka
    Kagawa University Faculty of Medicine, Kita-gun, Japan
  • Footnotes
    Commercial Relationships   Rie Osaka, None; Chieko Shiragami, None; Aoi Ono, None; Saki Manabe, None; Yukari Takasago, None; Mamoru Kobayashi, None; Ayana Yamashita, None; Kazuyuki Hirooka, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 811. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rie Osaka, Chieko Shiragami, Aoi Ono, Saki Manabe, Yukari Takasago, Mamoru Kobayashi, Ayana Yamashita, Kazuyuki Hirooka; One-year Outcomes of Fixed Treatment of Intravitreal Aflibercept for Exudative Age-related Macular Degeneration and the Factor of Visual Prognosis
      . Invest. Ophthalmol. Vis. Sci. 2018;59(9):811.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the efficacy of periodic intravitreal aflibercept (IVA) in exudative age-related macular degeneration (AMD), and potential predictors of visual outcome.

Methods : Fifty-two eyes of 52 treatment-naive AMD patients received IVA bimonthly following 3 monthly loading doses prospectively. Primary endpoints were changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT), and secondary outcomes included changes in subfoveal choroidal thickness (SCT), macular atrophy (MA), and average retinal sensitivity (AS) at 12 months compared with baseline. Potential predictors of change in BCVA were examined.

Results : Four patients dropped out, thus 48 were examined. Mean logMAR BCVA improved significantly (P = .008). CRT was significantly reduced at 12 months, as was SCT (P < .001). At 12 months, 72.3% exhibited a dry macula, and of these MA was evident in 20.0%. Mean AS at 12 months (17.6 dB) was significantly improved compared to baseline (15.4 dB) (P = .027). BCVA was significantly worse in cases with MA involving the fovea. Age and CRT at baseline were significant predictors of BCVA at 12 months.

Conclusions : IVA administered over 1 year improved BCVA, AS, and morphological characteristics. Age, baseline CRT, and MA involving the fovea were identified as predictors of BCVA.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×